에 대한 최신 뉴스 Utz Brands (NYSE:UTZ) 주식

Utz Brands

Utz Brands Inc is a snack food manufacturing company. It manufactures a diverse portfolio of salty snacks under popular brands including Utz, Zapp's, Golden Flake, Boulder Canyon, Hawaiian, TORTIYAHS!, among others. The company's products include potato chips, tortilla chips, pretzels, cheese snacks, pork skins, veggie snacks, pub/party mixes, and other snacks.. Its products are distributed nationally and internationally through grocery, mass merchant, club, convenience, drug, and other channels. It operates in the given segment: the manufacturing, distribution, marketing and sale of snack food products.

News

Small Cap

Markets

Trading Ideas

CHEF

VITL

캠벨 스프 (NYSE:CPB)는 견고한 공급망, 성공적인 혁신 및 효과적인 마케팅 프로그램으로 인해 어려운 소비자 환경 속에서도 탄력을 보여주고 있다.회사의 비용 절감 계획 또한 이러한 성공 이야기에 이바지하고 있다. 2024 회계 연도 2분기까지 회사는 스나이더스 랜스(Snyder&#39;s-Lance) 시너지를 포함한 여러 해 동안의 비용 절감 프로그램의 일환으로 9억 1500만 달러의 비용 절감을 발생시켰다. 경영진은 2025 회계 연도 말까지 10억달러 상당의 비용 절감을 실현할 것으로 예상되는 가운데 있는 것으로 보인다.

캠벨 수프(CPB)는 브랜드 강도를 바탕으로 회복력을 과시

Utz Brands Inc

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

Earnings

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that it has received a written notice (the "Notice") on November 14, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the quarter ended September 30, 2024 (the "Q3 2024 Form 10-Q") and because the Company remains delinquent in filing its Form 10-Qs for the quarters ended March 31, 2024 (the "Q1 2024 Form 10-Q") and June 30, 2024 (the "Q2 2024 Form 10-Q") and its Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K", and collectively with the Q1 2024 10-Q, Q2 2024 10-Q and Q3 2024 10-Q, the "Delinquent Filings"), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously announced, the Company received earlier notices of non-compliance with respect to the Rule on August 20, 2024, May 17, 2024 and April 2, 2024 because it had not yet filed its Q2 2024 Form 10-Q, Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.
This Notice has no immediate effect on the listing of the Company's shares on Nasdaq. However, if the Company fails to timely regain compliance with the Rule, the Company's common stock will be subject to delisting from Nasdaq.
As previously disclosed on October 7, 2024, the Company intended to appeal a determination by the Nasdaq Listing Qualifications Department to delist the Company's securities due to the Company's Delinquent Filings. On October 8, 2024, the Company timely requested a hearing before the Nasdaq Hearings Panel (the "Panel") and requested that the automatic stay of suspension be extended through the completion of the hearings process and the expiration of any additional extension period granted by the Panel following the hearing. The hearing is scheduled for November 26, 2024 and the request for the automatic stay of suspension was granted.
The Company is working diligently to complete its Delinquent Filings and will provide an update once more information is available.

LUNA

Luna Innovations Receives Additional Notice From Nasdaq Regarding Late Filing Of Quarterly Report On Form 10-Q; Hearing Is Scheduled For November 26, 2024 And The Request For The Automatic Stay Of Suspension Was Granted

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and raises the price target from $17 to $18.

Barrington Research Maintains Outperform on HireQuest, Raises Price Target to $18

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$3.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$3.5 Price Target

Lifeway Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) ("Lifeway" or the "Company"), a leading U.S. supplier of kefir and fermented probiotic products to support the microbiome, confirmed that it has received a revised, unsolicited, non-binding proposal from Danone North America PBC ("Danone") to acquire all outstanding shares of common stock of Lifeway it does not already own for $27.00 per share in cash. According to the Schedule 13D amendment filed today with the U.S. Securities and Exchange Commission disclosing the revised proposal, Danone beneficially owns approximately 23.3% of Lifeway's outstanding common stock.
On November 5, 2024, Lifeway announced that its Board of Directors (the "Board") had rejected Danone's initial unsolicited, non-binding proposal to acquire all the shares of Lifeway that it does not already own for $25.00 per share because the Board determined that the initial proposal substantially undervalued Lifeway and was not in the best interests of the Company and its shareholders and other stakeholders.
Consistent with its fiduciary duties, Lifeway's board of directors, in consultation with its independent outside advisors, will carefully review and evaluate the revised proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders and other stakeholders.
The Company does not undertake any obligation to provide any updates with respect to this or any other proposal or transaction, except as required under applicable law.
Lifeway shareholders do not need to take any action at this time.
Evercore is serving as a financial advisor to Lifeway and Sidley Austin LLP is serving as legal counsel to Lifeway.

LWAY

Lifeway Foods Confirms Receipt Of Revised, Unsolicited, Non-Binding Proposal From Danone  To Acquire All Outstanding Shares Of Common Stock Of Lifeway It Does Not Already Own For $27.00 Per Share In Cash

Generation Income (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIPR#NASDAQ">GIPR</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year. The company reported quarterly sales of $2.40 million which beat the analyst consensus estimate of $2.26 million by 6.21 percent. This is a 30.17 percent increase over sales of $1.84 million the same period last year.

Earnings Beats

GIPR

Generation Income Q3 FFO $(0.03), Same YoY, Sales $2.40M Beat $2.26M Estimate

Shareholders Approve Waiver Of 19.99% Limit To Enable Additional Stock Issuance

Stock Split

LUXH

LuxUrban Hotels Announces 1-For-70 Reverse Stock Split Effective Nov. 20 To Strengthen Nasdaq Compliance

Utz Brands backs full-year financial targets after solid quarter

Utz Brands, Inc. (UTZ) Q3 2024 Earnings Call Transcript

Utz Brands, Inc. (UTZ) Q3 2024 Management Session Earnings Call Transcript

Utz Brands Inc ( ($UTZ) ) has released its Q3 earnings. Here is a breakdown of the information Utz Brands Inc presented to its investors. Utz Brand...

Utz Brands Reports Strong Q3 2024 Earnings

Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on Wilmar International (WLMIF – Research Report)...

Analysts Have Conflicting Sentiments on These Consumer Goods Companies: Wilmar International (OtherWLMIF), UTZ Brands (UTZ) and Altria Group (MO)

Piper Sandler raised the firm's price target on Utz Brands (UTZ) to $24 from $22 and keeps an Overweight rating on the shares following third quart...

Utz Brands price target raised to $24 from $22 at Piper Sandler

In a report released yesterday, Brian Holland from D.A. Davidson maintained a Hold rating on UTZ Brands (UTZ – Research Report). The company's shar...

D.A. Davidson Reaffirms Their Hold Rating on UTZ Brands (UTZ)

John Baumgartner, an analyst from Mizuho Securities, maintained the Buy rating on UTZ Brands (UTZ – Research Report). The associated price target w...

UTZ Brands Positioned for Growth Amid Pricing Challenges: Buy Rating Reaffirmed

Mizuho lowered the firm's price target on Utz Brands (UTZ) to $21 from $24 and keeps an Outperform rating on the shares. The company's Q3's in-line...

Utz Brands price target lowered to $21 from $24 at Mizuho

TreeHouse Foods Crumbles Under Results, Listeria Concern

CALM

JJSF

SMPL

Press Releases

Utz Brands Releases 2023 Environmental, Social, and Governance Report

Utz Brands Provides Business Update at 2024 Barclays Global Consumer Staples Conference

Utz Brands, Inc. Declares Quarterly Cash Dividend

Utz Launches New Crunch & Flavor Campaign

Utz Brands Features New and Upcoming Flavors at NACS Show 2024

Utz Brands to Report Third Quarter 2024 Financial Results on October 31, 2024

Zapp's Rolls With Krewe of BOO!

Hydrofarm Holdings Group, Inc. Announces Leadership Succession Plan

Utz Brands Reports Third Quarter 2024 Results and Reaffirms 2024 Outlook

Utz Brands to Webcast Presentation at the Stephens Annual Investment Conference on November 20

CVGW

HYFM

Adecoagro

Mission Produce

B&G Foods

Beyond Meat

Cal-Maine Foods

Calavo Growers

Dole

Flowers Foods

The Hain Celestial Group, Inc. - Common Stock

Hain Celestial Group

John B. Sanfilippo & Son, Inc. - Common Stock

John B Sanfilippo & Son

J&J Snack Foods

WK Kellogg

Lancaster Colony Corporation - Common Stock

Lancaster Colony

Lifeway Foods

Mama`s Creations

Nomad Foods

Oatly Group AB - American Depositary Shares

Oatly Group

Post Hldgs

Seaboard

Seneca Foods Corp. - Class A Common Stock

Seneca Foods

The Simply Good Foods Company - Common Stock

Simply Good Foods

Treehouse Foods

Tootsie Roll Industries, Inc. Common Stock

Tootsie Roll Industries

Vital Farms

Westrock Coffee

Mizuho

Piper Sandler

Needham

Barclays

Stephens & Co.

<a class="author-name" href="https://www.benzinga.com/author/zacks" data-action="Clicked Author Link">Zacks</a>, Benzinga Contributor
캠벨 스프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>)는 견고한 공급망, 성공적인 혁신 및 효과적인 마케팅 프로그램으로 인해 어려운 소비자 환경 속에서도 탄력을 보여주고 있다. 
회사의 비용 절감 계획 또한 이러한 성공 이야기에 이바지하고 있다. 2024 회계 연도 2분기까지 회사는 스나이더스 랜스(Snyder&#8217;s-Lance) 시너지를 포함한 여러 해 동안의 비용 절감 프로그램의 일환으로 9억 1500만 달러의 비용 절감을 발생시켰다. 경영진은 2025 회계 연도 말까지 10억달러 상당의 비용 절감을 실현할 것으로 예상되는 가운데 있는 것으로 보인다.
<h3>CPB에게 잘 작용하는 것들</h3>
캠벨 스프는 포트폴리오 내 다양한 기회에 잘 대응할 수 있는 위치에 있으며 변화하는 소비 트렌드와 일치시키기 위한 여러 기회를 잡을 수 있는 위치에 있다. 회사의 전략과 계획은 다음 세 가지 핵심 영역에 중점을 두고 있다.
1) 마진 목표의 범위 내에서 제품 가격을 경쟁력 있게 유지하고 경제적인 가격을 보장하는 것
2) 마케팅 및 혁신 계획을 유지하는 것
3) 투자 수익률과 영향력 있는 계획에 중점을 둔 수입 절복적 및 균형 있는 지출 방침을 준수하는 것.
이어지는 혁신 정책과 소보스 브랜즈(SOVOS Brands)의 인수가 보조되면서 캠벨 스프는 식품 산업에서의 위치를 단단히 다지고 가속화된 성장을 보일 수 있을 것으로 예상됩니다. 이번 인수는 캠벨의 밀 앤 비버리지(Meals &amp; Beverages) 포트폴리오를 라오(Rao)의 소스, 마이클 앤젤로(Michael Angelo&#8217;s)의 브랜드 및 누사(noosa)와 같은 고성장 브랜드로 강화한다. 소보스 브랜즈는 캠프벨에 파스타 소스, 건파스타, 수프, 냉동식품, 냉동 피자 및 요거트와 같은 프리미엄 제품군을 가져온다.
계속 진행 중인 이러한 추진력과 2024년 3월에 완료된 소보스 브랜즈의 인수를 통해 캠벨 스프는 높은 성장판을 구축하고 견고한 위치에 있다. 이런 이유로 캠벨 스프에는 비용의 하락과 수익의 증가에 연관되어있는 이점이 어느때보다 많아졌다. 비즈니스에서의 이익을 이끌어내기 위한 관리의 직접적인 점포 배송(DSD) 변환 프로젝트는 스낵 부문에서의 추가 성장과 이익을 기대하고 있다. 이 프로젝트는 3가지 핵심 요소를 통해 이루어질 것으로 예상된다. 첫번째는 스낵 DSD 로지스틱스 및 창고 네트워크를 하나로 조합하는 것, 두번째는 회사의 중요한 독립적 유통 파트너가 사용하는 도구 및 기술을 현대화하는 것 , 세번째는 DSD 경로에 중점을 둔 것이다.
<h3>기타 알아둬야할 사항</h3>
캠벨 스프는 변동성이 높은 소비자 풍토를 탐색하고 있다. 2024 회계 연도 2분기에 회사의 매출 비중은 43.7%를 차지한 스낵 사업으로부터 혜택을 보았다. 이 사업 부문의 순매출은 이번 분기 기준 유기적 기준으로 1% 증가한 7억 2500만달러를 기록하였으며 이는 8가지의 파워브랜드의 매출 급증 (4%) 이라는 결과로 이어졌다. 경제적인 현실이 더욱 어려워진 가운데 Goldfish, Lance, Kettle Brand 및 Cape Cod와 같은 브랜드의 강점으로 인해 매출이 강화된 것으로 보인다. 경영진은 DSD 전략을 통해 Snacks 부문에서의 더 많은 성장과 이익이 예상된다고 말하고 있다. 이는 다음과 같은 세 가지 핵심 요소를 통해 이루어 질 것으로 예상된다. 1) 스낵 DSD 로지스틱스 및 창고 네트워크를 하나로 조합하는 것 2) 회사의 중요한 독립적 유통 파트너가 사용하는 도구 및 기술을 현대화하는 것 3) DSD 경로에 중점을 둔 것이다.
<h3>다른 사항들</h3>
캠벨 스프는 변동성이 높은 소비자 풍토를 탐색하고 있다. 2024 회계 연도 2분기에 회사의 매출 비중은 43.7%를 차지한 스낵 사업으로부터 혜택을 보았다. 회사의 2024 회계 연도 2분기에는 연간 기준으로 다소 낮아진 소프트 볼륨/믹스(전년 동기대비 2% 감소)가 1% 상승한 순 가격실현 때문에 유기적 순매출이 1% 감소했다. 이러한 사업 중심의 영향으로 캠벨 스프의 매출은 1% 줄었지만 이는 기대를 하던 것보다 나은 성과이다. 근래 경제의 풍향이 갈수록 어려워지고 있는 가운데로 인해 일부 카테고리와 소비자 인구통계학적 요소에 영향을 미칠 것으로 보인다. 2024 회계 연도 중 회사는 당초 보고된 숫자들에 비해 0.5% 감소부터 1.5% 증가 사이의 순매출 유지를 예상하고 있다. 유기적 매출은 평평한 수준에서 2%까지의 증가를 보일 것으로 예상된다. 둘째 분기에 발표된 이익 보고서에 따르면 회사의 경영진은 캠벨 스프의 2024 회계 연도의 순매출에 대한 전망의 하측으로 진행하고 있다고 밝혔으며, 이에 따라 올해 내내 순차적인 개선을 지켜보고 있다. 3분기에는 회사의 경영진은 유기적 매출을 기준으로 수준이 하향되어 2학기에 이어 4분기에도 순차적인 증가가 예상된다고 말했다. 캠벨 스프는 장기간에 걸쳐 비용 인플레이션이 있었고, 기업은 2024 회계 연도 동안 주요 인플레이션 비율이 단일 숫자 범위 내에서 유지될 것으로 예상하고 있다. 회사는 2024 회계 연도 동안 브랜드 관련 투자를 지속할 것으로 예상하고 있습니다. 회사의 경영진은 올 해 회사의 마케팅 및 판매 비용 예산이 올 해 회계 연도 9월과 12월 사이에 총 매출의 9%에서 10% 사이로 늘어날 것으로 예상하고 있다. 그렇지만 회사는 올해 2분기에 기대 이익과 마진 개선을 통해 주로 4분기에 경제적인 풍토 개선이 나타날 것으로 예상하고 있다. 이러한 변화는 지속적인 생산성 향상 및 용량 추세의 증가를 통해 반영될 것으로 보인다.
캠벨 스프는 2024 회계 연도 동안 조정된 EBIT가 3-5% 증가할 것으로 예상된다. 조정된 EPS는 3-5% 증가하여 3.09~3.15%로 예상된다. 3분기에는 최근 1년간 68센트였던 EPS보다 낮은 70센트 정도의 EPS가 예상된다. 캠벨 스프의 주식은 지난 6개월 동안 15.3% 라는 산업의 성장률에 비해 11.5%의 상승을 기록했다.
<h3>맛있는 배팅 3선</h3>
The Chef&#8217;s Warehouse(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>)는 특수식품 제품을 유통하는 회사로 현재 Zacks Rank #2 (Buy)를 기록 중이다. CHEF의 지난 4분기 평균 이익은 3.2%를 기록하였습니다. The Zacks Consensus Estimate에 따르면, The Chef&#8217;s Warehouse의 현재 회계연도 매출 및 이익은 작년 동기대비 각각 8.7% 및 4.7% 씩 증가할 것으로 예상된다. Vital Farms Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>)은 각종 농장에서 생산한 식품을 제공하는 회사로 현재 Zacks Rank #2 (Buy)를 기록 중인다. VITL의 지난 4분기 평균 이익은 155.4%를 기록하였다. Vital Farms의 Zacks 콘센서스 추정치에 따르면, 현재 회계연도 회사의 매출과 이익은 작년 동기대비 각각 18.6% 및 35.6% 씩 증가할 것으로 예상된다. Utz Brands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>)는 다양한 종류의 허절고 간식을 생산하는 회사로 현재 Zacks Rank #2 (Buy)를 기록 중이다. UTZ의 지난 4분기 평균 이익은 2.6%를 기록하였다. Utz Brands의 현재 회계연도 이익에 대한 Zacks 콘센서스 추정치에 따르면, 작년 동기대비 17.5% 씩의 증가가 예상된다.

Comments

Utz Brands

뉴스

에 대한 최신 뉴스 Utz Brands (NYSE:UTZ) 주식

토요일, 4월 06, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌